|
| 36915208 | Pharmacogenomic profiling reveals molecular features of chemotherapy resistance in IDH wild-type primary glioblastoma. | Genome Med | 2023 |
| 37792958 | Identifying predictors of glioma evolution from longitudinal sequencing. | Sci Transl Med | 2023 |
| 37788099 | The semaphorin 3A/neuropilin-1 pathway promotes clonogenic growth of glioblastoma via activation of TGF-β signaling. | JCI Insight | 2023 |
| 36972629 | Dopamine receptor D2 regulates glioblastoma survival and death through MET and death receptor 4/5. | Neoplasia | 2023 |
| 34738209 | Effects of Long-Term In Vitro Expansion on Genetic Stability and Tumor Formation Capacity of Stem Cells. | Stem Cell Rev Rep | 2022 |
| 35666535 | Somatic genomic landscape of East Asian epithelial ovarian carcinoma and its clinical implications from prospective clinical sequencing: A Korean Gynecologic Oncology Group study (KGOG 3047). | Int J Cancer | 2022 |
| 35657027 | Recapitulated Crosstalk between Cerebral Metastatic Lung Cancer Cells and Brain Perivascular Tumor Microenvironment in a Microfluidic Co-Culture Chip. | Adv Sci (Weinh) | 2022 |
| 35994815 | Calcipotriol, a synthetic Vitamin D analog, promotes antitumor immunity via CD4+T-dependent CTL/NK cell activation. | Biomed Pharmacother | 2022 |
| 35882469 | Corrigendum to "Combination effect of poly (ADP-ribose) polymerase inhibitor and DNA demethylating agents for treatment of epithelial ovarian cancer" [Gynecologic Oncology, Volume 165, Issue 2, May 2022, Pages 270-280]. | Gynecol Oncol | 2022 |
| 36009433 | Combination of Dexamethasone and Tofacitinib Reduces Xenogeneic MSC-Induced Immune Responses in a Mouse Model of Alzheimer's Disease. | Biomedicines | 2022 |
| 35067843 | Correction to: Effects of Long-Term In Vitro Expansion on Genetic Stability and Tumor Formation Capacity of Stem Cells. | Stem Cell Rev Rep | 2022 |
| 35305818 | Combination effect of poly (ADP-ribose) polymerase inhibitor and DNA demethylating agents for treatment of epithelial ovarian cancer. | Gynecol Oncol | 2022 |
| 34986867 | Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial. | Genome Med | 2022 |
| 34862196 | Genomic Landscape and Clinical Utility in Korean Advanced Pan-Cancer Patients from Prospective Clinical Sequencing: K-MASTER Program. | Cancer Discov | 2022 |
| 33479772 | Modulation of Nogo receptor 1 expression orchestrates myelin-associated infiltration of glioblastoma. | Brain | 2021 |
| 33494793 | Comprehensive molecular characterization of gastric cancer patients from phase II second-line ramucirumab plus paclitaxel therapy trial. | Genome Med | 2021 |
| 33828082 | Mutation-specific non-canonical pathway of PTEN as a distinct therapeutic target for glioblastoma. | Cell Death Dis | 2021 |
| 33846173 | Determinants of Response and Intrinsic Resistance to PD-1 Blockade in Microsatellite Instability-High Gastric Cancer. | Cancer Discov | 2021 |
| 31096737 | Clinical Targeted Next-Generation sequencing Panels for Detection of Somatic Variants in Gliomas. | Cancer Res Treat | 2020 |
| 32070411 | Comprehensive pharmacogenomic characterization of gastric cancer. | Genome Med | 2020 |
| 32636318 | A Phase II Trial of Tipifarnib for Patients with Previously Treated, Metastatic Urothelial Carcinoma Harboring <i>HRAS</i> Mutations. | Clin Cancer Res | 2020 |
| 32605068 | Multi-Habitat Radiomics Unravels Distinct Phenotypic Subtypes of Glioblastoma with Clinical and Genomic Significance. | Cancers (Basel) | 2020 |
| 32794373 | Ethnic delineation of primary glioblastoma genome. | Cancer Med | 2020 |
| 32620753 | Integrated pharmaco-proteogenomics defines two subgroups in isocitrate dehydrogenase wild-type glioblastoma with prognostic and therapeutic opportunities. | Nat Commun | 2020 |
| 32847614 | Transcriptional regulatory networks of tumor-associated macrophages that drive malignancy in mesenchymal glioblastoma. | Genome Biol | 2020 |
| 32753598 | MGMT genomic rearrangements contribute to chemotherapy resistance in gliomas. | Nat Commun | 2020 |
| 32532977 | ARS2/MAGL signaling in glioblastoma stem cells promotes self-renewal and M2-like polarization of tumor-associated macrophages. | Nat Commun | 2020 |
| 30536544 | Hypermutagenesis in untreated adult gliomas due to inherited mismatch mutations. | Int J Cancer | 2019 |
| 31748746 | Longitudinal molecular trajectories of diffuse glioma in adults. | Nature | 2019 |
| 31850215 | Systematic Evaluation of Gastric Tumor Cell Index and Two-Drug Combination Therapy via 3-Dimensional High-Throughput Drug Screening. | Front Oncol | 2019 |
| 29939324 | Identification of genomic and molecular traits that present therapeutic vulnerability to HGF-targeted therapy in glioblastoma. | Neuro Oncol | 2019 |
| 30085274 | Distinct genomic profile and specific targeted drug responses in adult cerebellar glioblastoma. | Neuro Oncol | 2019 |
| 30898893 | PIP4K2A as a negative regulator of PI3K in PTEN-deficient glioblastoma. | J Exp Med | 2019 |
| 31044160 | The combination of neoantigen quality and T lymphocyte infiltrates identifies glioblastomas with the longest survival. | Commun Biol | 2019 |
| 30804471 | Ly6G<sup>+</sup> inflammatory cells enable the conversion of cancer cells to cancer stem cells in an irradiated glioblastoma model. | Cell Death Differ | 2019 |
| 29129044 | Anti-SEMA3A Antibody: A Novel Therapeutic Agent to Suppress Glioblastoma Tumor Growth. | Cancer Res Treat | 2018 |
| 30202050 | A tension-mediated glycocalyx-integrin feedback loop promotes mesenchymal-like glioblastoma. | Nat Cell Biol | 2018 |
| 30343896 | Mutational Landscape of Secondary Glioblastoma Guides MET-Targeted Trial in Brain Tumor. | Cell | 2018 |
| 30262818 | Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy. | Nat Genet | 2018 |
| 29573206 | Identification of transcriptome signature for predicting clinical response to bevacizumab in recurrent glioblastoma. | Cancer Med | 2018 |
| 29715102 | Pharmacokinetics, Biodistribution, and Toxicity Evaluation of Anti-SEMA3A (F11) in <i>In Vivo</i> Models. | Anticancer Res | 2018 |
| 29600313 | Comparison of 1p and 19q status of glioblastoma by whole exome sequencing, array-comparative genomic hybridization, and fluorescence in situ hybridization. | Med Oncol | 2018 |
| 27901492 | Genomic and transcriptomic characterization of skull base chordoma. | Oncotarget | 2017 |
| 28263318 | Spatiotemporal genomic architecture informs precision oncology in glioblastoma. | Nat Genet | 2017 |
| 28754668 | Transglutaminase 2 Inhibition Reverses Mesenchymal Transdifferentiation of Glioma Stem Cells by Regulating C/EBPβ Signaling. | Cancer Res | 2017 |
| 28902178 | Tumor Inhibitory Effect of IRCR201, a Novel Cross-Reactive c-Met Antibody Targeting the PSI Domain. | Int J Mol Sci | 2017 |
| 28917835 | Antitumor activity, pharmacokinetics, tumor-homing effect, and hepatotoxicity of a species cross-reactive c-Met antibody. | Biochem Biophys Res Commun | 2017 |
| 26783102 | Involvement of DDX6 gene in radio- and chemoresistance in glioblastoma. | Int J Oncol | 2016 |
| 27102443 | Anti-miR delivery strategies to bypass the blood-brain barrier in glioblastoma therapy. | Oncotarget | 2016 |
| 26023737 | In vivo RNAi screen identifies NLK as a negative regulator of mesenchymal activity in glioblastoma. | Oncotarget | 2015 |